Back

Efficacy and safety of inclisiran in reducing LDL cholesterol and triglycerides: real-life experience in a third level hospital: a descriptive, bivariate, and multivariate analysis.

4 April 2025 (09:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Poster session (2) Drug therapy EAPC Premium Access ESC Preventive Cardiology 2025 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Doctor Juan Jose Macancela Quinonez

Hospital Torrecardenas, Almeria (Spain)

87 More presentations in this session

Presentation thumbnail
Comparative efficacy and safety of antithrombotic regimens following left atrial appendage occlusion therapy in atrial fibrillation patients: a comprehensive Bayesian network meta-analysis
Doctor V. Lanari (Milan, IT)
Abstract Slides
Presentation thumbnail
Paroxysmal atrial fibrillation prediction score based on 24-hours electrocardiogram-monitoring data
Doctor G. Galati (Milan, IT)
Abstract Slides
Presentation thumbnail
Is excessive epicardial fat volume in asymptomatic young adult subjects with normal calcium score the trigger for abnormal ECGs and arrhythmia?
Doctor A. Sabatini (Florence, IT)
Abstract Slides
Presentation thumbnail
Prevention of readmission in the acute setting for heart failure patients: an adapted protocol of levosimendan infusion in inpatient high-intensity cardiac rehabilitation
Doctor I. Cusmano (Milan, IT)
Abstract Slides
Presentation thumbnail
Enhanced external counterpulsation (EECP) as a strategy for left ventricular and microcirculatory improvement: independent of cardiac intervention
Doctor O. Handayani (Jakarta, ID)
Abstract Slides

Access the full session

Session thumbnail
Poster session (2)

The Event

Event poster

ESC Preventive Cardiology 2025

4 April 2025 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of inclisiran monotherapy in patients with hypercholesterolemia without background lipid-lowering therapy: a systematic review and meta-analysis
thumbnail
Congress Presentation
Efficacy of inclisiran versus placebo in atherosclerotic cardiovascular disease: A systematic review and meta-analysis
thumbnail
Congress Presentation
Boosting secondary prevention: efficacy and adherence of inclisiran in post-acute coronary syndrome very high-risk patients

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources